SELLAS Life Sciences (SLS) Liabilities and Shareholders Equity (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $114.2 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 226.63% year-over-year to $114.2 million in Q1 2026; TTM through Mar 2026 was $276.4 million, a 187.86% increase from a year earlier, with the FY2025 full-year figure at $78.3 million, up 303.18% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $114.2 million, up from $78.3 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for SLS reached as high as $114.2 million in Q1 2026 and fell as low as $6.2 million in Q4 2023.
• Historically, Liabilities and Shareholders Equity has averaged $32.9 million across 5 years, with a median of $26.0 million in 2022.
• Across the five-year window, Liabilities and Shareholders Equity slumped 70.31% in 2023 and soared 303.18% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $20.9 million in 2022, then slumped by 70.31% to $6.2 million in 2023, then surged by 212.46% to $19.4 million in 2024, then surged by 303.18% to $78.3 million in 2025, then soared by 45.74% to $114.2 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $114.2 million in Q1 2026, $78.3 million in Q4 2025, and $51.6 million in Q3 2025.